Wednesday, July 05, 2023
InnoCare Pharma announced that the first patient with psoriasis has received a dosage of ICP-488, their TYK2 JH2 allosteric inhibitor, in a clinical trial conducted in China.
The phase I clinical trial has successfully completed the stages of single ascending doses (SAD) and multiple ascending doses (MAD), demonstrating a well-tolerated safety profile for ICP-488.
The ongoing study focuses on evaluating the safety and efficacy of ICP-488 in patients with moderate-to-severe psoriasis. ICP-488 is a potent and selective TYK2 allosteric inhibitor that has been specifically developed for the treatment of psoriasis and other autoimmune diseases.
By binding to the JH2 domain, ICP-488 effectively blocks the signal transduction of various inflammatory cytokines, including IL-23, IL-12, and type 1 IFN. This mechanism inhibits the pathological processes associated with autoimmune and inflammatory diseases.
Autoimmune diseases, including psoriasis, present significant unmet needs in terms of treatment options. The progress made in dosing the first psoriasis patient in this clinical trial marks an important milestone in the development of ICP-488 as a potential treatment option for psoriasis.
Psoriasis is a chronic immune-mediated disease that can affect patients' physical health, quality of life and work productivity. Despite the advancements in treatment options over the years, there remains a significant unmet demand for more effective therapies, particularly in the form of oral medications.
